Clinical Trial

Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma

Study acronym: CLeAR
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Randomized, 2-arm, non-comparative, pilot study assessing the efficacy of cemiplimab with or without fianlimab after treatment with yttrium-90 (Y90).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-01-16; most recent amendment 2026-03-24.
Trial Details
NCT Number NCT07365839
Lead Sponsor Virginia Commonwealth University
Collaborators: Regeneron Pharmaceuticals
Conditions Hepatocellular Carcinoma
Enrollment 20 participants
Start Date 2026-07-01
Primary Completion 2035-02-28 (estimated)
Study Completion 2035-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-25